Activation of intrarenal complement system in mouse model for chronic cyclosporine nephrotoxicity

Yonsei Medical Journal

Volumn 48, Issue 3, 2007, Pages 517-525

  Kim, Young Ok ^a   Lim, Sun Woo ^a   Li, Can ^a,b   Kang, Hee Jung ^c   Ahn, Kyung Ohk ^a   Yang, Hyun Joo ^a   Ghee, Jung Yeon ^a   Kim, Su Hyun ^a   Kim, Jin Young ^a   Choi, Bun Soon ^a   Kim, Jin ^a   Yang, Chul Woo ^a  

^a The Catholic University of Korea   (South Korea)

^b YANBIAN UNIVERSITY   (China)

^c Hallym University College of Medicine   (South Korea)

Author keywords

Complement; Cyclosporine; Innate immunity; Nephrotoxicity

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C9; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYCLOSPORIN A; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; REGULATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC TOXICITY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTERSTITIAL NEPHRITIS; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; MALE; MORPHOMETRICS; MOUSE; NEPHROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; SODIUM RESTRICTION; UPREGULATION;

ANIMALS; ANTIGENS, CD45; ANTIGENS, CD46; ANTIGENS, CD55; COMPLEMENT C3; COMPLEMENT C4B; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT SYSTEM PROTEINS; CYCLOSPORINE; DISEASE MODELS, ANIMAL; IMMUNITY, NATURAL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; MICE; MICROSCOPY, CONFOCAL; PEPTIDE FRAGMENTS;

EID: 34447553324     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2007.48.3.517     Document Type: Article

References (35)

1. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-66.
2. Walport MJ. Complement. Second of two parts. N Engl J Med 2001;344:1140-4.
3. Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol 2005;16:1195-204.
4. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998;97:2259-67.
5. Yamada K, Miwa T, Liu J, Nangaku M, Song WC. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol 2004;172:3869-75.
6. Sogabe H, Nangaku M, Ishibashi Y, Wada T, Fujita T, Sun X, et al. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J Immunol 2001;167: 2791-7.
7. Sacks SH, Zhou W, Andrews PA, Hartley B. Endogenous complement C3 synthesis in immune complex nephritis. Lancet 1993;342:1273-4.
8. Hsu SI, Couser WG. Chronic progression of tubulo-interstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors? J Am Soc Nephrol 2003;14 (7 Suppl 2):S186-91.
9. Nangaku M, Pippin J, Couser WG. C6 mediates chronic progression of tubulointerstitial damage in rats with remnant kidneys. J Am Soc Nephrol 2002;13:928-36.
10. Nangaku M, Alpers CE, Pippin J, Shankland SJ, Kurokawa K, Adler S, et al. CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats. J Am Soc Nephrol 1998;9:590-7.
11. Qin X, Goldfine A, Krumrei N, Grubissich L, Acosta J, Chorev M, et al. Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes 2004;53:2653-61.
12. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002;8:582-7.
13. Li C, Lim SW, Sun BK, Yang CW. Chronic cyclosporine nephrotoxicity: new insights and preventive strategies. Yonsei Med J 2004;45:1004-16.
14. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001;7:384-9.
15. Yang CW, Faulkner GR, Wabba IM, Christianson TA, Bagby GC, Jin DC, et al. Expression of apoptosis-related genes in chronic cyclosporine nephrotoxicity in mice. Am J Transplant 2002;2:391-9.
16. Mazzali M, Hughes J, Dantas M, Liaw L, Steitz S, Alpers CE, et al. Effects of cyclosporine in osteopontin null mice. Kidney Int 2002;62:78-85.
17. Turnberg D, Botto M, Warren J, Morgan BP, Walport MJ, Cook HT. CD59a deficiency exacerbates accelerated nephrotoxic nephritis in mice. J Am Soc Nephrol 2003; 14:2271-9.
18. Tang S, Sheerin NS, Zhou W, Brown Z, Sacks SH. Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells. J Am Soc Nephrol 1999;10:69-76.
19. Welch TR, Beischel LS, Witte DP. Differential expression of complement C3 and C4 in the human kidney. J Clin Invest 1993;92:1451-8.
20. Collins AB, Schneeberger EE, Pascual MA, Saidman SL, Williams WW, Tolkoff-Rubin N, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999;10:2208-14.
21. Mroz A, Lewandowski Z, Cieciura T, Matlosz B, Pazik J, Kwiatkowski A, et al. C4d complement split product in diagnosis of immunological activity of chronic allograft nephropathy. Transplant Proc 2006;38:97-100.
22. Straatsburg IH, Boermeester MA, Wolbink GJ, van Gulik TM, Gouma DJ, Frederiks WM, et al. Complement activation induced by ischemia-reperfusion in humans: a study in patients undergoing partial hepatectomy. J Hepatol 2000;32:783-91.
23. Chang T, Chowdhry S, Budhu. P, Kew RR. Smokeless tobacco extracts activate complement in vitro: a potential pathogenic mechanism for initiating inflammation of the oral mucosa. Clin Immunol Immunopathol 1998; 87:223-9.
24. Nangaku M, Pippin J, Couser WG. Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol 1999;10:2323-31.
25. Rangan GK, Pippin JW, Coombes JD, Couser WG. C5b-9 does not mediate chronic tubulointerstitial disease in the absence of proteinuria. Kidney Int 2005; 67:492-503.
26. Endoh M, Yamashina M, Ohi H, Funahashi K, Ikuno T, Yasugi T, et al. Immunohistochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues. Clin Exp Immunol 1993;94:182-8
27. Cosio FG, Sedmak DD, Mahan JD, Nahman NS Jr. Localization of decay accelerating factor in normal and diseased kidneys. Kidney Int 1989;36:100-7.
28. Tamai H, Matsuo, S, Fukatsu A, Nishikawa K, Sakamoto N, Yoshioka K, et al. Localization of 20-kD homologous restriction factor (HRF20) in diseased human glomeruli. An immnunofluorescence study. Clin Exp Immunol 1991;84:256-62.
29. Lim SW, Li C, Ahn KO, Kim J, Moon IS, Ahn C, et al. Cyclosporine-induced renal injury induces toll-like receptor and maturation of dendritic cells. Transplantation 2005;80:691-9.
30. Li C, Yang CW, Park JH, Lim SW, Sun BK, Jung JY, et al. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 2004;286:F46-57.
31. Shagdarsuren E, Wellner M, Braesen JH, Park JK, Fiebeler A, Henke N, et al. Complement activation in angiotensin II-induced organ damage. Circ Res 2005;97: 716-24.
32. Pasch MC, Van Den Bosch NH, Daha MR, Bos JD, Asgbar SS, Synthesis of complement components C3 and factor B in human keratinocytes is differentially regulated by cytokines. J Invest Dermatol 2000;114:78-82.
33. Lee EK, Kang SM, Paik DJ, Kim JM, Youn J. Essential roles of Toll-like receptor-4 signaling in arthritis induced by type II collagen antibody and LPS. Int Immunol 2005;17:325-33.
34. Xin J, Homma T, Matsusaka T, Ma J, Isaka. Y, Imai E, et al. Suppression of cyclosporine a nephrotoxicity in vivo by transforming growth factor beta receptor-immunoglobulin G chimeric protein. Transplantation 2004;77: 1433-42.
35. Lee CT, Huynh VM, Lai LW, Lien YH. Cyclosporine A-induced hypercalciuria in calbindin-D28k knockout and wild-type mice. Kidney Int 2002;62:2055-61.